These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 1286752)

  • 21. Regulatory considerations for marker vaccines and diagnostic tests in the U.S.
    Foley PL; Hill RE
    Biologicals; 2005 Dec; 33(4):253-6. PubMed ID: 16257538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of autogenous biologicals in the United States.
    Schmellik-Sandage CS; Hill RE
    Dev Biol (Basel); 2004; 117():9-13. PubMed ID: 15597610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marketing authorization of veterinary medicinal products in Poland.
    Sztabińska-Koncka H; Lewicki J
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):129-33. PubMed ID: 9339489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative Methods to Reduce, Refine, and Replace the Use of Animals In the Development and Testing of Veterinary Biologics in The United States; a Strategic Priority.
    Hill RE
    Procedia Vaccinol; 2011; 5():141-145. PubMed ID: 32288916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Licensing Requirements for Poultry Veterinary Biologics in the United States.
    Schrader JS; Smith HE
    Avian Dis; 2024 Jan; 67(4):467-473. PubMed ID: 38300665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Food and Drug Administration regulations and licensure.
    Barker LF
    Fed Proc; 1975 May; 34(6):1522-4. PubMed ID: 1126452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Registration of veterinary drugs in Australia and New Zealand.
    Hotson IK
    J S Afr Vet Assoc; 1981 Jun; 52(2):131-4. PubMed ID: 7196954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Revision of the requirements for constituent materials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Apr; 76(71):20513-8. PubMed ID: 21491807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterizing biological products and assessing comparability following manufacturing changes.
    Chirino AJ; Mire-Sluis A
    Nat Biotechnol; 2004 Nov; 22(11):1383-91. PubMed ID: 15529163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. United States Department of Agriculture licensing requirements for feline leukemia virus vaccines.
    Shibley GP; Tanner JE; Hanna SA
    J Am Vet Med Assoc; 1991 Nov; 199(10):1402-6. PubMed ID: 1666091
    [No Abstract]   [Full Text] [Related]  

  • 32. United States Department of Agriculture: requirements for sterility testing veterinary biologics.
    Koski TA
    Dev Biol Stand; 1974; 23():169-73. PubMed ID: 4459192
    [No Abstract]   [Full Text] [Related]  

  • 33. Summary of Veterinary Services tests of biologics 1978-1979.
    Price RJ
    Proc Annu Meet U S Anim Health Assoc; 1979; (83):63-5. PubMed ID: 298938
    [No Abstract]   [Full Text] [Related]  

  • 34. A 4R concept for the safety testing of immunobiologicals.
    Cussler K
    Dev Biol Stand; 1999; 101():121-6. PubMed ID: 10566784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hazard identification and risk assessment for biologics targeting the immune system.
    Weir AB
    J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and approval of vaccines in the United States.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presentation of the directive 81/852/EEC (92/18) safety testing.
    Vannier P
    Dev Biol Stand; 1992; 79():47-50. PubMed ID: 1286765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory control of blood products in Canada.
    Boucher DW; Furesz J
    Dev Biol Stand; 1987; 67():221-8. PubMed ID: 3609478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability.
    Davis GC; Beals JM; Johnson C; Mayer MH; Meiklejohn BI; Mitlak BH; Roth JL; Towns JK; Veenhuizen M
    Curr Med Res Opin; 2009 Jul; 25(7):1655-61. PubMed ID: 19476407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.